Literature DB >> 35341404

Canine and murine models of osteosarcoma.

Jessica Beck1, Ling Ren1, Shan Huang1, Erika Berger1, Kathleen Bardales1,2, Joshua Mannheimer1, Christina Mazcko1, Amy LeBlanc1.   

Abstract

Osteosarcoma (OS) is the most common malignant bone tumor in children. Despite efforts to develop and implement new therapies, patient outcomes have not measurably improved since the 1980s. Metastasis continues to be the main source of patient mortality, with 30% of cases developing metastatic disease within 5 years of diagnosis. Research models are critical in the advancement of cancer research and include a variety of species. For example, xenograft and patient-derived xenograft (PDX) mouse models provide opportunities to study human tumor cells in vivo while transgenic models have offered significant insight into the molecular mechanisms underlying OS development. A growing recognition of naturally occurring cancers in companion species has led to new insights into how veterinary patients can contribute to studies of cancer biology and drug development. The study of canine cases, including the use of diagnostic tissue archives and clinical trials, offers a potential mechanism to further canine and human cancer research. Advancement in the field of OS research requires continued development and appropriate use of animal models. In this review, animal models of OS are described with a focus on the mouse and tumor-bearing pet dog as parallel and complementary models of human OS.

Entities:  

Keywords:  canine; comparative oncology; dogs; experimental animal models; metastasis; mice; murine models; osteosarcoma; review; veterinary clinical trials

Mesh:

Year:  2022        PMID: 35341404      PMCID: PMC9290378          DOI: 10.1177/03009858221083038

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   3.157


  178 in total

1.  Osteoblastic and osteolytic human osteosarcomas can be studied with a new xenograft mouse model producing spontaneous metastases.

Authors:  Jun Yuan; Christian Ossendorf; Jan P Szatkowski; James T Bronk; Avudaiappan Maran; Michael Yaszemski; Mark E Bolander; Gobinda Sarkar; Bruno Fuchs
Journal:  Cancer Invest       Date:  2009-05       Impact factor: 2.176

2.  Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial.

Authors:  K A Skorupski; J M Uhl; A Szivek; S D Allstadt Frazier; R B Rebhun; C O Rodriguez
Journal:  Vet Comp Oncol       Date:  2013-10-04       Impact factor: 2.613

3.  Site incidence of canine osteosarcoma.

Authors:  R E Wolke; S W Nielsen
Journal:  J Small Anim Pract       Date:  1966-07       Impact factor: 1.522

4.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

5.  Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.

Authors:  Motonari Nomura; Nino Rainusso; Yi-Chien Lee; Brian Dawson; Cristian Coarfa; Ruolan Han; Jeffrey L Larson; Ryan Shuck; Lyazat Kurenbekova; Jason T Yustein
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 13.506

6.  Use of routine histopathology and factor VIII-related antigen/von Willebrand factor immunohistochemistry to differentiate primary hemangiosarcoma of bone from telangiectatic osteosarcoma in 54 dogs.

Authors:  M A Giuffrida; N J Bacon; D A Kamstock
Journal:  Vet Comp Oncol       Date:  2016-08-09       Impact factor: 2.613

7.  Development of a new canine osteosarcoma cell line.

Authors:  B Séguin; T Zwerdling; J L McCallan; H E V DeCock; L L Dewe; D K Naydan; A E Young; D L Bannasch; O Foreman; M S Kent
Journal:  Vet Comp Oncol       Date:  2006-12       Impact factor: 2.613

Review 8.  Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.

Authors:  Michael S Isakoff; Stefan S Bielack; Paul Meltzer; Richard Gorlick
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

9.  Two distinct cell lines derived from a human osteosarcoma.

Authors:  A Kawai; T Ozaki; S Ikeda; T Oda; M Miyazaki; J Sato; K Taketa; H Inoue
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

Review 10.  Osteosarcoma in the Post Genome Era: Preclinical Models and Approaches to Identify Tractable Therapeutic Targets.

Authors:  Wilson Castillo-Tandazo; Anthony J Mutsaers; Carl R Walkley
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

View more
  1 in total

Review 1.  Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment.

Authors:  Cassidy M Van Stiphout; Anita K Luu; Alicia M Viloria-Petit
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.